Major listed companies in the industry: Aojing Medical (688613);Zhenghai Bio (300653);Chunli Medical(688236);Wego Orthopedics (688161);Kellytai (300326).
-- North America has the highest market share
In the global orthopedic bone defect repair materials market, North America has long dominated the revenue market;The European market occupies the second largest share;The Asia-Pacific market has been the fastest-growing region in recent years, due in part to the increasing geriatric population and the rising level of orthopedic surgeryRevenue growth in the Middle East, Africa, and Latin America markets was relatively low. In 2022, North America accounted for about 40% of the global orthopedic bone defect repair materials market.
——North American orthopedic bone defect repair material manufacturers have strong competitiveness
From the perspective of global orthopedic bone defect repair material manufacturers, the main foreign orthopedic bone defect repair material manufacturers include Medtronic, Depuy Synthes (a subsidiary of Johnson & Johnson), and Stryker, which are mainly distributed in North America. China's major manufacturers of orthopedic bone defect repair materials include Aojing Medical, Ruibang Biotech and Yangsheng Biotech.
-- The supply of domestic products and imported products coexists
From the perspective of the supply of orthopedic bone defect repair materials in China, according to incomplete statistics, as of November 2023, among the registered products of orthopedic bone defect repair materials in China, there are more than 35 domestic products and more than 25 imported products.
-- The purpose of mergers and acquisitions is mostly for overseas enterprises to enter the Chinese market
There are few mergers and acquisitions in China's orthopedic bone defect repair materials industry, mainly because the world's leading companies enter the Chinese market through mergers and acquisitions.
Specifically, the foreign investment purposes of Aojing Medical, Zhenghai Biotechnology, Chunli Medical, Weigao Orthopedics, Xinkangchen Medical, Lianhe Biology and Yapeng Biotechnology all involve the expansion of business scale, and the foreign investment purposes of Zhenghai Biotechnology, Chunli Medical, Weigao Orthopedics and Yapeng Biotechnology include the layout of downstream, and only the foreign investment objectives of Aojing Medical and Chunli Medical involve the layout of downstream raw materials.
-- The process of domestic substitution continues to advance
Local enterprises have accelerated technology research and development, continued to promote the technological progress of orthopedic bone defect repair materials in China, and helped the domestic substitution process of orthopedic bone defect repair materials in China continue to advance.
At present, the products of foreign-funded enterprises such as Johnson & Johnson, Stryker, and Medtronic in the orthopedic bone defect repair materials market are highly competitive. From the perspective of domestic substitution in the orthopedic bone defect repair materials industry, the number of domestic product registrations of China's orthopedic bone defect repair materials was 0 before the Eleventh Five-Year PlanSince the Twelfth Five-Year Plan, with the continuous technological breakthroughs of domestic enterprises, the number of domestic product registrations has grown rapidly, and domestic substitution has been accelerating. During the 14th Five-Year Plan period, with the continuous enhancement of the overall strength of domestic enterprises and the strong support of national policies, there is still a great potential for domestic substitution, and as of November 2023, 18 orthopedic bone defect repair material products have been registered.
Note: 1) The above statistical keywords include "bone repair materials", "bone cement", etc.;2) The statistical date is November 17, 2023;3) There are many types and naming methods of orthopedic bone defect repair materials, and the above are incomplete statistics.
For more research and analysis of this industry, please refer to the "Market Prospect and Investment Strategic Planning Analysis Report of China Orthopedic Bone Defect Repair Materials Industry" by Qianzhan Industry Research Institute.
At the same time, the Prospective Industry Research Institute also provides solutions such as industrial big data, industrial research reports, industrial planning, park planning, industrial investment, industrial map, smart investment promotion system, industry status certification, IPO consulting, fundraising and investment feasibility study, and IPO working paper consulting. Quotation of this article in any public information disclosure, such as prospectus, annual report of the company, etc., requires formal authorization from the Prospective Industry Research Institute.